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The peptide VTGRFAGHPAAQ revealed the highest 
α-glucosidase inhibitory activity (IC50 = 365.4 µg/mL). 
A novel nutraceutical effect for peptides from an egg 
yolk hydrolysate was shown.
Keywords Egg yolk protein by-product · Hydrolysis · 
Antioxidant · Antidiabetic · Angiotensin I-converting 
enzyme inhibitory activity
Introduction
Diet-related diseases such as cardiovascular disease, obe-
sity, hypertension and diabetes mellitus (DM) represent sig-
nificant health problems worldwide and there is evidence to 
suggest a possible common pathophysiology among type 2 
DM, cardiovascular disease and oxidative stress.
DM is an endocrine system disease that causes metabolic 
disorders leading to multiple organ damage syndromes. 
The most effective therapy for DM is the maintenance of 
optimal blood glucose levels (Matsui et al. 1996; Yu et al. 
2012). Accordingly, an effective strategy for the control of 
DM type 2 is the use of inhibitors of α-glucosidase which 
catalyzes the cleavage of d-glucose from oligosaccharides 
and disaccharides, and the inhibitors of dipeptidyl pepti-
dase-4 (DPP-4) which participates in the rapid decomposi-
tion of GLP-1, a hormone increasing the secretion of insu-
lin by the pancreatic beta cells and decreasing the secretion 
of glucagon after meal (Matsui et al. 1996; Lacroix and 
Li-Chan 2012). DM type 2 can lead to serious complica-
tions including organs damage, such as renal failure. Insu-
lin resistance is also related to hypertension (Matsui et al. 
1996).
Hypertension is one of the major risk factors for car-
diovascular disease (Miguel et al. 2004). Substances 
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displaying inhibitory activity against dipeptidyl carboxy-
peptidase (angiotensin-converting enzyme or ACE, EC 
3.4.15.1) play an important role in controlling the develop-
ment of hypertension by regulating the renin–angiotensin 
system. Angiotensin I is a substrate for ACE which pro-
duces angiotensin II by removing the C-terminal dipeptide 
(HL) from angiotensin I. Angiotensin II, by causing mus-
cle contraction in small blood vessels, significantly raises 
the blood pressure and increases the heart rate. ACE also 
removes the C-terminal dipeptide of bradykinin (a vasodi-
lator), resulting in the creation of an inactive peptide frag-
ment (Ondetti and Cushman 1999). Therefore, inhibition of 
ACE activity is considered an effective approach to control 
hypertension.
Reactive oxygen species (ROS) are natural by-products 
of normal oxygen metabolism and have important roles 
in cell signaling and homeostasis. ROS have a significant 
role including inactivation of nitric oxide (Cai and Harrison 
2000). However, dramatic increases in ROS result in signif-
icant damage to human cells by altering proteins, lipids and 
DNA. The imbalance in redox state causes oxidative stress, 
endothelial dysfunction and reduction of NO availability 
(Hadi et al. 2005). Finally, this leads to several simultane-
ous processes which may culminate in vascular damage 
and hypertension (Touyz et al. 2003).
Antioxidants, as well as peptides, are compounds capa-
ble of inhibiting oxidative reactions and protecting the 
human body against the destructive activity of free radicals. 
Numerous studies have been undertaken to develop novel 
bioactive peptides from food proteins. The aforementioned 
dependencies between the etiologies of various diseases 
indicate the special importance of multifunctional peptides: 
their combined antioxidant, ACE inhibitory and antidia-
betic properties would make a useful peptide preparation 
for the control and prevention of diet-related diseases.
There is a need for natural and easily bio-renewable 
materials that could be used to obtain bioactive food addi-
tives and medicines used in the treatment of various medi-
cal conditions (Mine and Kovaks-Nolan 2006; Yu et al. 
2012). One example of such material is egg yolk, provid-
ing well-known egg-derived bioactive substances such as 
lysozyme, cystatin, avidin, phosvitin and phospholipids. 
Recently, there has been a significant increase in studies 
of modification of egg components to improve or evaluate 
other biological activities. Representative examples include 
dimerization of lysozyme, egg phosphatidylcholine enrich-
ment in polyunsaturated fatty acids and enzymatic hydrol-
ysis of ovalbumin (Lesnierowski et al. 2004; Gładkowski 
et al. 2011; Yu et al. 2011).
Enzymatic hydrolysis is one of the most important and 
widely used technologies in obtaining bioactive peptides 
from egg proteins. These peptides, released from the pro-
teins by the action of proteolytic enzymes, have various 
beneficial health effects in the circulatory, nervous and 
immune systems. Egg protein-derived bioactive peptides 
include opioid peptides, peptides lowering high blood pres-
sure, inhibiting platelet aggregation, carriers of metal ions 
and peptides with immunostimulatory, antimicrobial, anti-
diabetic and antioxidant activity (Mine and Kovaks-Nolan 
2006; Yu et al. 2011).
In recent years, researchers in this area have been look-
ing for unconventional high-performance enzymes, devel-
oping hydrolysis methods for the isolation of peptides and 
technologies based mainly on the use of native proteins. In 
addition, the preparation of bioactive peptides by enzymatic 
hydrolysis of proteinaceous by-products could become an 
interesting method of waste disposal. It also seems desir-
able to be able to use the entire egg as a source of biologi-
cally active substances, including any by-products gener-
ated in the process of isolation of these substances.
Nowadays, egg yolks are intensively used for the extrac-
tion of valuable phospholipids. Delipidated egg yolk pro-
teins (YP) are the main by-products of lecithin extraction 
from egg yolk. The delipidation process, using ethanol and 
hexane for the removal of phospholipids, impairs protein 
functionality and so the YP possess limited biological and 
biotechnological value (Jiang et al. 2001; Ting et al. 2011). 
YP by-products, however, can be converted into value-
added products with functional and biological properties 
improved by enzymatic hydrolysis.
The aim of the study was to obtain peptides with antiox-
idant and ACE inhibitory activities as well as antidiabetic 
properties, via enzymatic hydrolysis of a by-product that 
had been generated from the isolation of egg yolk phospho-
lipids, and to confirm their biological properties.
Materials and methods
Substrate
40–45-week-old Lohmann brown line laying hens were 
housed in a bedding system. Eggs were automatically 
broken open and macroscopic parts were separated on an 
industrial scale. An egg yolk protein preparation (YP), 
the by-product of phospholipid extraction using ethanol 
(Siepka et al. 2010), was used as a substrate. The YP was 
dephosphorylated before enzymatic hydrolysis (Xu et al. 
2007) and was then lyophilized and stored frozen until fur-
ther use.
Enzyme
Enzymatic hydrolysis was performed using commercially 




Determination of proteolytic activity
Proteolytic activity was determined in a reaction with 
2 % hemoglobin as a substrate and incubated for 10 min 
at 37 °C. The reaction was halted by the addition of 5 % 
trichloroacetic acid (TCA). The samples were then centri-
fuged, and the absorbance of supernatants was measured 
at λ = 280 nm. One unit of enzymatic activity (U) was 
defined as the amount of enzyme giving an increase in 
absorbance at 280 nm of 0.1 under reaction conditions.
Determination of protein content
The total protein (N × 6.25) in the insoluble substrate was 
determined using the Kjeldahl method. Protein content in 
hydrolysates and peptide fractions were determined by the 
Lowry et al. method (1951) using BSA (Sigma P0834) as a 
standard.
Enzymatic hydrolysis
YP hydrolysis was carried out according to a modified 
method by Zambrowicz et al. (2013). A substrate suspen-
sion (10 %) in 0.02 M Gly-HCl buffer (pH 3.5) was hydro-
lyzed at 37 °C for 2 h using pepsin at a dose of 20 U/mg 
of hydrolyzed YP. The reaction was quashed by heating 
at 100 °C for 10 min. The hydrolysate was cooled, centri-
fuged (5,500×g, 10 min, 10 °C) and the supernatant was 
lyophilized and stored at 4 °C until further use.
The degree of hydrolysis
Degree of hydrolysis (%) was determined by measuring 
TCA soluble protein (Silvestre 1996).
Determination of ACE inhibitory activity
The ACE (EC 3.4.15.1; from rabbit lung, Sigma, A6778) 
inhibitory activity of hydrolysate and peptide fractions was 
measured spectrophotometrically according to Miguel et al. 
(2004). A hydrolysate solution (40 µL) mixed with a Hip-
puryl-His-Leu (HHL) (Sigma H4884) solution (5 mM in 
100 mM potassium phosphate containing 300 mM sodium 
chloride, pH 8.3) as substrate was preincubated at 37 °C for 
5 min, and the reaction was initiated by adding 20 µL (2 mU) 
of ACE solution and incubating for 30 min at the same tem-
perature. The enzymatic reaction was halted by the addi-
tion of 150 µL of 1 M HCl. The liberated hippuric acid was 
extracted using 1 mL of ethyl acetate and vigorous shaking, 
after which 750 µL of the upper layer was transferred into a 
test tube and evaporated in a vacuum. The hippuric acid left 
in the tubes was re-dissolved in 800 µL of distilled water and 
the absorbance was measured at λ = 228 nm. All samples 
were tested in three replications. The inhibition activity was 
calculated using the following equation:
Inhibition activity (%) = [(A − B)/A] × 100 %
where A is the reaction blank, of which the mixture con-
tained the same volume of the buffer solution instead of the 
ACE inhibitor sample; B is the reaction in the presence of 
both ACE and its inhibitor. The IC50 value was estimated 
from a dose–response curve of an inhibitor versus the ACE 
activity.
Determination of antioxidant activity as the ability 
to scavenge DPPH free radicals
The antioxidant activity of the obtained hydrolysates was 
assessed on the basis of the radical scavenging effect of 
the stable 1,1-diphenyl-2-picrylhydrazyl [DPPH (Sigma, 
D21140-0)]—free radical activity according to Yen and 
Chen (1995), with minor modifications. The tested sam-
ples were dissolved in water to a final volume of 1 mL 
and mixed with 1 mL of ethanol (98 %). The reaction was 
started by adding 0.5 mL of 0.3 M DPPH in ethanol. The 
mixtures were left for 30 min at room temperature and 
the absorbance of the resulting solutions was measured 
at 517 nm. For calibration, aqueous solutions of known 
Trolox concentrations ranging from 2 to 20 μg (able to 
scavenge 500 μL of 0.3 mM DPPH radical solution) were 
used. Radical scavenging activity of the peptides was 
expressed as µM troloxeq/mg protein.
FRAP method
The ferric reducing antioxidant power (FRAP) method 
was used to determine the antioxidative capacity of hydro-
lysates according to Benzie and Strain (1996). 3 mL of 
FRAP working solution [300 mM acetate buffer pH 3.6; 
10 mM 2,4,6,tripyridyl-s-triazine (TPTZ) (Fluka, 93285) 
and 20 mM FeCl3 × 6 H2O (10:1:1 v/v)] was mixed with 
1 mL of the sample. After 10 min of reaction, the absorb-
ance was measured at λ = 593 nm. An aqueous solution of 
known Fe(II) concentration was used for calibration (in the 
range from 100 to 1,000 μg). Results were expressed as μg 
Fe2+/mg protein.
Determination of Fe(II) ion chelation
Chelation of iron ions by hydrolysates was estimated 
by the method of Xu et al. (2007) with modifications. 
A 250 μL sample was mixed with 1,250 μL H2O and 
110 μL 1 mM FeCl2. After 2 min, 1 mL of 500 μM fer-
rozine (Sigma 160601) aqueous solution was added and 
the mixture was allowed to react for 10 min. The absorb-
ance of ferrous iron–ferrozine complex was measured 
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spectrophotometrically at λ = 562 nm. A known concen-
tration of FeCl2 (0–20 μg) was used to generate a standard 
curve and the ability to chelate iron ions was expressed as 
μg Fe2+/mg protein.
α-Glucosidase inhibitory activity
The α-glucosidase inhibition assay was performed accord-
ing to the method of Yu et al. (2011). α-Glucosidase from 
Saccharomyces cerevisiae (Sigma G0660) hydrolyzes the 
substrate—p-nitrophenyl glucopyranoside (pNPG) (Sigma 
N1377) and the thus produced p-nitrophenol can be meas-
ured spectrophotometrically. 5 µL of the α-glucosidase 
solution (10 U/mL, in 0.1 M potassium phosphate buffer, 
pH 6.8) was premixed with 10 µL of the sample solution 
at different concentrations (in 10 % DMSO) in 620 µL of 
0.1 M potassium phosphate buffer (pH 6.8). Following 
incubation at 37.5 °C for 20 min, 10 µL of p-nitrophenyl 
glucopyranoside (pNPG 10 mM) as substrate was added 
to the mixture to start the reaction and was then incubated 
at 37.5 °C for 30 min, followed by addition of 650 µL of 
1 M Na2CO3 solution to terminate the reaction. The amount 
of released product (p-nitrophenol) was measured at 
λ = 410 nm. The IC50 value was defined as the concentra-
tion of inhibitor required to inhibit 50 % of α-glucosidase 
activity under assay conditions.
Dipeptidyl peptidase-4 (DPP-4) inhibitory activity
DPP-4 inhibitory activity (IC50) was determined using a 
modified method of Lacroix and Li-Chan (2013). DPP-4 
from porcine kidney was purchased from Sigma (D7052). 
The lyophilized peptide fractions were re-suspended in 
0.1 M Tris–HCl buffer, pH 8.0. The test sample (25 μL) 
was preincubated with an equal volume of the substrate 
Gly-Pro-p-nitroanilide (1.6 mM) at 37 °C for 10 min. 
Afterwards, 50 μL of DPP-4 (0.01 U/mL, in 0.1 M Tris–
HCl buffer, pH 8.0) was added and the mixture was incu-
bated at 37 °C for 60 min. The reaction was stopped by the 
addition of 100 μL of 1 M sodium acetate buffer, pH 4.0. 
The released p-nitroanilide as a hydrolysis product was 
measured at λ = 405 nm.
The IC50 value was defined as the concentration of 
inhibitor required to inhibit 50 % of DPP-4 activity under 
assay conditions.
Ion‑exchange chromatography
First, to remove unhydrolyzed protein (mainly phosvitin), 
the peptic hydrolysate of YP was precipitated [pH adjust-
ment to 4.0 left overnight at 4 °C, then centrifuged (5,500g, 
10 min, 4 °C)], and the obtained supernatant was used fur-
ther. Ion-exchange chromatography was performed using a 
SP Sephadex c-50 resin (Pharmacia Fine Chemicals, 1569) 
(column size 1.5 × 11.0 cm) with a BioLogic LP (Bio-Rad) 
system. The operation conditions were as follows: phase 
A: 0.02 M acetate buffer pH 3.5; phase B: 0.02 M acetate 
buffer pH 3.5 with 1 M NaCl, gradient: 0.5 % B/min; flow 
rate: 0.5 mL/min; and fraction volume: 2 mL. The absorb-
ance of eluents was monitored at λ = 235 nm.
Reversed-phase high-performance liquid chromatography
Peptide profiles of hydrolysates were estimated by 
reversed-phase high-performance liquid chromatography 
(RP-HPLC) with an Agilent 1100 Series system. Separa-
tion was performed using a Zorbax XDB-C 18 Agilent 
column [4.5 × 250 mm (for fraction 4), 1.8 × 50 mm (for 
peptic hydrolysate and fraction 4.3)] at T = 30 °C. The 
starting phase (A) was 0.1 % TFA (Fluka) in water and the 
eluting phase (B) was 0.1 % TFA in acetonitrile (LabScan). 
The other operation conditions were varied; peptic hydro-
lysate: flow rate 1 mL/min, gradient: from the second min-
ute of analysis 5 % B/min; fraction 4: flow rate: 1 mL/min, 
gradient: 5 min 0 % B, 5–45 min 15 % B, 45–50 min 30 % 
B, fraction 4.3: flow rate: 0.5 mL/min, gradient: 2 min 0 % 
B, 2–22 min 10 % B, 22–30 min 15 % B. The absorbance 
of eluents was monitored at λ = 235 nm.
RP-HPLC purification and analysis of peptides obtained 
by the chemical synthesis were carried out using Varian 
ProStar and Thermo Separation Product liquid chromato-
graphs. Separations were performed on a YMC-Pack ODS-
AQ12S05-2546WT column with a Guard Column and a 
TSKgel ODS-120T 12TG08eh004 column also equipped 
with a Guard Column, with a linear elution gradient of 
0–80 % B in A: A (0.1 % TFA in water) and B (80 % CH 3 
CN in water + 0.1 % TFA), at flow rates of 7 mL/min and 
1 mL/min for the Varian ProStar and Thermo Separation 
Product equipment, respectively.
Determination of peptide molecular weight and sequence 
and analysis of chemically synthesized peptides
The peptide fraction obtained by RP-HPLC was lyophi-
lized. Then the sample was dissolved in 1 mL 60 % ace-
tonitrile, centrifuged and evaporated. The peptide sample 
was dissolved again in 60 μL 60 % acetonitrile. 40 μL 
of this solution was evaporated to dryness in a centrifu-
gal evaporator and was then dissolved in 10 µL of 50 % 
(v/v) acetonitrile. 0.5 µL of this peptide solution was then 
mixed with 0.5 µL of alpha-cyano-4-hydroxycinnamic 
acid solution, pipetted onto a steel plate and evaporated 
to dryness. MALDI-ToF analysis was performed using 
UltrafleX-treme apparatus (Bruker Daltonics, Germany) 
in positive-ion mode. The MS and MS/MS spectra were 
collected and processed using FlexControl, FlexAnalysis, 
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BioTools as well as ProteinScape software (Bruker Dal-
tonics, Germany), while protein sequences were identified 
using a MASCOT server (Matrix Science, USA) and the 
UniProtKB/SwissProt protein sequences database (version 
25.10.2012, European Bioinformatics Institute, UK). Dur-
ing searching, the taxonomy of the source organism was 
restricted to Gallus gallus, and to the possible modifica-
tions of polypeptide chains to methionine oxidation. No 
restrictions concerning peptidase specificity during peptide 
processing were declared.
Analysis of the chemically synthesized peptides was 
carried out using a HR-ESI-MS (FT-ICR Apex-Qe Ultra 
7 T, Bruker Daltonics, Bremen, Germany) equipped with 
a standard electrospray ion source. The instrument was 
operated in the positive-ion mode. The instrument was 
calibrated using a TuneMix™ mixture (Bruker Daltonics, 
Bremen, Germany). The solution used for the measure-
ments was CH3CN/H2O/HCOOH (50: 50: 0.1, v/v/v), with 
a range of values from 100 to 1,800 m/z.
Chemical synthesis of the peptides
Chemical synthesis of the peptides was carried out at 
the Faculty of Chemistry at the University of Wrocław 
(Poland). The synthesis of specific peptides was carried 
out manually in a syringe reactor (BRAUN Inject, Ger-
many). Preloaded Wang resins (0.58–0.79 mM/g) (Iris 
Biotech GmbH) were used for the synthesis of fully pro-
tected peptides. Fmoc-protecting group (9-fluorenylmeth-
yloxycarbonyl) was removed with 25 % piperidine solu-
tion (Sigma-Aldrich) in DMF (3 and 17 min) (Carl Roth 
GmbH + Co. KG). Amino acid coupling reaction was car-
ried out using DMF as a solvent with the use of 3 equiva-
lents TCTU (Iris Biotech GmbH) as the coupling reagent, 
three equivalents of HOBt [GL Biochem (Shanghai) Ltd.], 
and six equivalents of DIEA (Iris Biotech GmbH) as addi-
tives. The reactions were carried out for 150 min. Pep-
tides were cleaved from the resin simultaneously with side 
chain deprotection using a mixture of TFA (Iris Biotech 
GmbH)/TIS (Alfa Aesar)/H2O (95: 2.5: 2.5, v/v/v). The 
reaction was carried out for 120 min. Then, the solution 
was transferred into cold diethyl ether (Sigma-Aldrich). 
The crude residue was collected, dissolved in water, lyo-
philized and purified by reversed-phase high-performance 
liquid chromatography. All peptides were obtained as their 
trifluoroacetate salts.
Statistical analysis
Each type of hydrolysates was prepared in two independ-
ent batches. The biological activity measurements of 
hydrolysates as well as various fractions obtained in the 
purification process were done in triplicate for each batch. 
Statistical significance of the differences was determined 
by the Duncan’s t test (p < 0.05).
Results and discussion
Preparation of biologically active peptides from the egg 
yolk protein by-product
Numerous studies have been undertaken to develop novel, 
natural and safe biologically active peptides from food pro-
tein sources. However, only a few researchers have focused 
on protein by-products as a fairly inexpensive source of 
biopeptides. One such protein waste is delipidated egg yolk 
protein (YP), a by-product of phospholipid extraction from 
egg yolk (Ting et al. 2011; Siepka et al. 2010). In this study, 
YP was hydrolyzed with porcine pepsin. The hydrolysis was 
necessary to release the antioxidant and ACE inhibitory pep-
tides from the inactive forms of intact YP by-product. After 
a 2-h reaction the extent of the protein was estimated by 
assessing the degree of hydrolysis (DH) and peptide profile 
analysis (RP-HPLC). The hydrolysis rate was 45.3 %. The 
RP-HPLC profiles of YP peptic hydrolysate were charac-
terized by numerous peaks varying in their hydrophobicity 
(Fig. 1a). An increase in antioxidant and ACE inhibitory 
activity was observed as a result of the hydrolysis. The peptic 
hydrolysate demonstrated significant increases in DPPH free 
radical scavenging, ferric reducing power (FRAP) and iron 
chelating activities, achieving values of 0.5 µM Troloxeq/mg, 
56.4 µg Fe2+/mg, and 405.0 µg Fe2+/mg, respectively.
The peptic (2-h) hydrolysate of YP possessed a remark-
ably higher FRAP (12.7 times) and iron chelating (33.8 
times) activity than a 4-h peptic hydrolysate obtained in 
previous work, which may be attributed to the higher DH 
(2.37 times) (Zambrowicz et al. 2012). The presented 
results are in accordance with our earlier study in which 
hydrolysates obtained from a phosvitin protein preparation 
treated by trypsin and protease from A. melleus exhibited a 
comparable ferric reducing power with values of 24.0 and 
31.3 µg Fe2+/mg (Zambrowicz and Trziszka 2010).
Our results confirm the observations of other authors 
that enzymatic hydrolysates of egg yolk proteins may 
exert stronger antioxidant activity. Peptide fractions (MW 
<5 kDa) from protein hydrolysate of lecithin free egg yolk 
prepared with Alcalase exhibited activities as reflected in 
TBA and PV that were 30 and 43 % better than that for 
α-tocopherol (Park et al. 2001). Additionally, Sakanaka and 
Tachibana (2006) reported that hydrolysates prepared by 
sequential hydrolysis of egg yolk, conducted with first ori-
entase and then with protease from Bacillus ssp., showed 
strong antioxidant activity. DPPH and hydroxyl radical 
scavenging activities (at 0.5 % of the hydrolysates) were 
74.2 and 91.7 %, respectively.
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The peptic hydrolysate of YP also exhibited a significant 
ACE inhibitory activity (IC50 = 623.0 μg/mL). The IC50 
value of the peptic hydrolysate of YP was not comparable 
to other values reported for enzymatic hydrolysates of egg 
yolk proteins. The level of this activity for egg yolk hydro-
lysates prepared with the use of gastrointestinal (pepsin, 
pancreatin) and non-gastrointestinal (thermolysin, alkalase) 
proteases ranged from 133.4 to 210.2 µg/mL (You and Wu 
2011). The different levels of antihypertensive activity in 
our study might have resulted from the use of YP by-prod-
uct instead of whole egg yolk in its native form.
Yoshi et al. (2001) obtained peptides of 1 kDa or less 
with ACE inhibitory activity by the hydrolysis of egg yolk 
with a crude enzyme. These peptides act by lowering sys-
tolic blood pressure in rats, in a dose-dependent manner, 
and the study implied that peptides extracted from chicken 
egg yolk could potentially suppress the development of 
hypertension in SHR, and this effect might be induced by 
the inhibition of ACE activity (Yoshi et al. 2001).
On the other hand, our own results showed that peptic 
YP hydrolysate possessed significantly higher ACE inhibi-
tory activity than hydrolysates obtained from egg white 
proteins. Fujita et al. (2000) demonstrated that hydrolysates 
obtained from ovalbumin using pepsin and thermolysin 
exhibited ACE inhibitory activity with IC50 values of 45 
and 83 mg/mL, respectively.
Isolation and purification of bioactive peptide
The peptic hydrolysate of YP was precipitated (pH 4.0) 
and centrifuged to remove unhydrolyzed protein (mainly 
phosvitin). The antioxidant and ACE inhibitory activi-
ties of the obtained supernatant were significantly higher 
than the 2-h hydrolysate (Table 1). Then, to find pep-
tides exhibiting a potential biological effect, the obtained 
supernatant was subjected to ion-exchange chromatog-
raphy by LC on a SP-Sephadex c-50 resin (Fig. 1b). The 
procedure allowed for the isolation of six fractions (1–6) 
which were collected, concentrated by lyophilization and 
then evaluated for antioxidant and ACE inhibitory activi-
ties. Two peptide fractions: 1 (IC50 = 249.0 µg/mL) and 4 
(IC50 = 283.1 µg/mL) with ACE inhibitory activity were 
obtained (Table 1). Additionally, fraction no. 4 exerted the 
strongest antioxidant activity among all the obtained frac-
tions, with DPPH free radical scavenging, ferric reduc-
ing power (FRAP) and iron chelating activity reaching: 
2.9 µM Troloxeq/mg, 110.6 µg Fe2+/mg, and 250.1 µg 
Fig. 1  Scheme of peptide isolation from peptic egg yolk protein by-
product (YP) hydrolysate. a Peptide profile (RP-HPLC) of 2 h hydro-
lysate; b ion-exchange chromatography; c RP-HPLC of fraction no 4; 




Fe2+/mg, respectively. This fraction was further purified 
by RP-HPLC on a Zorbax C18 column and the eluate was 
divided into eight major fractions (A–H) (Fig. 1c). The 
analysis of all collected fractions showed a wide diversity 
in the levels of antioxidant and ACE inhibitory activity. 
The strongest ACE inhibitory activity (IC50 = 35.0 µg/mL) 
was estimated for fraction C (Table 1). Furthermore, frac-
tion D was also a strong inhibitor and two times higher 
than that necessary to deactivate 50 % of the enzyme 
with fraction C. Similar to the previous step of the isola-
tion procedure, only one fraction, C, was characterized by 
a strong antioxidant activity of; DPPH radical scavenger 
(3.0 µM Troloxeq/mg), ferric reducer (112.1 µg Fe2+/mg) 
and iron chelator (106.5 µg Fe2+/mg).
Interestingly, our work indicated that peptide fractions 
from YP hydrolysate possessed strong combined DPPH 
radical scavenging and ACE inhibitory activities. This was 
in accordance with a study conducted by Lu et al. (2010), 
in which enzymatic hydrolysates with high ACE inhibitory 
activity usually also possessed high levels of DPPH radi-
cal scavenging activity. This was also observed by Davalõs 
et al. (2004) who described the ovalbumin-derived pep-
tide Tyr–Ala–Glu–Glu–Arg–Tyr–Pro–Ile–Leu. It had a 
strong ACE inhibitory activity, also possessing high radical 
scavenging activity, and delayed low-density lipoprotein 
lipid oxidation induced by Cu2+ ions.
The chromatogram obtained during further chromatog-
raphy (RP-HPLC) of fraction C indicated the presence of 
one main peptide peak (Fig. 1d).
Purification of the YP preparation resulted in a signifi-
cant increase in ACE inhibitory and DPPH radical scaveng-
ing activity compared to the original hydrolysate, indicat-
ing the effectiveness of the isolation procedure. At the same 
time, the proposed procedure had no significant impact on 
the level of iron chelating or ferric reducing activity.
Amino acid sequence and characteristics of purified 
peptides
Fraction C with the highest antioxidant and ACE inhibitory 
activity was subjected to MALDI-ToF analysis to iden-
tify its amino acid sequence. The MS spectrum presented 
in Fig. 2 revealed four major signals at m/z = 926.549, 
1,211.708, 1,464.813 and 1,678.975, respectively, accom-
panied by a large group of low-intensity signals (among 
them m/z = 1,393.774) below a 1,600 m/z value. Unfor-
tunately, the peaks of the substances corresponding 
to the minor signals were too low to perform MS/MS 
Table 1  Biological activities of the peptide fractions separated by precipitation, ion-exchange and reverse-phase chromatography of 2-h egg 
yolk protein by-product (YP) hydrolysate treated by pepsin
All data were expressed as mean values (n = 3)
Values sharing the same letter are not significantly different at p < 0.05
Mean values with different letters in the same column are significantly different at p ≤ 0.05
NA no activity
Isolation step Sample ACE IC50 (µg/mL) DPPH (µM Troloxeq/mg) FRAP (µg Fe2+/m) CHEL (µg Fe2+/mg)
Hydrolysis Peptic hydrolysate (2 h) 
(DH 45.3 %)
623.0a 0.5h,i 56.4f 405.0b
Precipitation (pH 4.0; 
centrifugation)
Supernatant 361.0d 1.6d,e 78.1d 458.6a
Ion-exchange chromatog-
raphy
1 249.1e 0.54hi 70.5e 13.2h
2 291.5d 0.55hi 23.3i 94.6f
3 NA 1.5d 15.1j 109.3f
4 283.0d 2.9b 110.6c 250.1c
5 475.8b 1.4e NA 128.2e
6 NA 0.67gh NA 38.3g
RP-HPLC A NA NA NA NA
B 152.3f 1.9c 112.1c NA
C (4.C) 35.0h 3.0ab 184.2b 406.5b
D 72.7g 0.8g 76.3de 175.6d
E 245.9e 0.8g 54.7f NA
F 423.0c 1.0f 40.0g NA
G NA NA 31.2h NA
H NA 0.4i 25.6hi 27.3gh
4.C.1 29.0h 3.1a 190.8a 402.5b
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analysis; therefore, we focused our attention on the 
major signals at m/z = 926.549, 1,211.708, 1,464.813 
and 1,678.975. Mascot search result analysis revealed 
that the signals at m/z = 1,393.774 [M+H+]+ and 
m/z = 1,464.813 [M+H+]+ corresponded to the single-
protonated fragments of Apolipoprotein B (YINQMPQK-
SRE and YINQMPQKSREA, respectively), and the sig-
nals at m/z = 1,211.708 [M+H+]+ and m/z = 1,678.975 
[M+H+]+ corresponded to single-protonated fragments of 
Vitellogenin-2 (VTGRFAGHPAAQ) and Apovitellenin-1 
(YIEAVNKVSPRAGQF), respectively (Fig. 3).
ACE inhibitory peptides usually contain 3–13 amino 
acid residues (Li et al. 2004). Thus, the molecular weights 
of most YP-derived peptides were in good agreement with 
the size of the reported ACE inhibitory peptide.
To confirm antioxidant and ACE inhibitory activ-
ity, the YP-derived peptides were synthetized and tested 
(Table 2). Furthermore, antidiabetic activity, as reflected in 
α-glucosidase and DPP-IV inhibitory properties, was deter-
mined. The resulting peptides were characterized by a high 
purity (determined by RP-HPLC) of 91–99 % (Table 2). 
Almost all of them exerted triple activities: antioxidant, 
ACE-inhibitory and antidiabetic. Individual synthetic pep-
tides showed lower antioxidant activity than those pooled in 
the mixture (fraction C). In contrast, IC50 values of the syn-
thesized peptides were significantly higher than those for 
fraction C (Tables 1, 3). Peptide YINQMPQKSRE revealed 
the strongest antioxidant activity. The DPPH free radical 
scavenging and iron chelating activities reached 2.3 µM 
Troloxeq/mg and 37.4 µg Fe2+/mg, respectively. However, 
peptide YINQMPQKSREA differed with the presence of 
alanine at the C-terminal sequence, and was characterized 
by the highest ferric reducing activity (76.0 µg Fe2+/mg). 
Antioxidative peptide YINQMPQKSRE also demon-
strated very strong ACE (IC50 = 10.1 µg/mL) and DPP-
IV (IC50 = 222.8 µg/mL) inhibitory activity. Additionally, 
the level of DPP-IV inhibitory activity for that peptide 
was the highest among all the tested peptides. The strong-
est ACE inhibitory activity with IC50 = 9.4 µg/mL was 
yielded by the sequence YIEAVNKVSPRAGQF. This pep-
tide exerted at the same time relatively strong antioxidant 
activity. The DPPH free radical scavenging, ferric reducing 
and iron chelating activities reached 2.2 µM Troloxeq/mg, 
61.0 and 25.0 µg Fe2+/mg, respectively. However, peptide 
YIEAVNKVSPRAGQF, which was characterized as the 
most effective ACE inhibitor, had no impact on the activity 
of α-glucosidase or DPP-IV.
Fig. 2  Determination of peptide molecular weight and sequence. MS-Maldi-ToF spectrum of fraction C isolated from 2-h egg yolk protein by-
product (YP) hydrolysate
Fig. 3  Mascot search results analysis of MS spectrum of pep-
tide fraction C. a Apovitellenin-1 peptide: IYEAVNKVSPRAGQF, 
b apolipoprotein B peptide: YINQMPQKSREA; c Vitellogenin-2 
peptide: VTGRFAGHPAAQ; d apolipoprotein B peptide: YIN-
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The highest level of α-glucosidase inhibitory activ-
ity (IC50 = 365.4 µg/mL) was exhibited by peptide 
VTGRFAGHPAAQ.
Representative examples of multifunctional food-derived 
peptides are fragments obtained during gastrointestinal 
digestion of lysozyme (Rao et al. 2012). These peptides 
exert strong competitive ACE inhibitory and remarkable 
antioxidant activity. Some other multifunctional peptides 
can be released from milk proteins. Peptides from sequence 
60–70 of β-casein show immunostimulatory, opioid and 
ACE inhibitory activities (Sharma et al. 2011).
According to Rao and others (2012), proteins containing 
a high proportion of hydrophobic and positively charged 
residues have the potential to generate multifunctional 
peptides. The percentage content of hydrophobic and posi-
tively charged residues in YP-derived peptides was in the 
range from 36.1 to 75.0 % (Table 3).
Among several of the amino acids, tyrosine is gener-
ally accepted as an antioxidant in spite of a pro-oxidative 
effect. Commonly, among the analyzed peptides herein 
with the strongest antioxidant activity is the presence of 
tyrosine at the N-terminus or at the second position of the 
N-terminal sequence. In contrast, His-containing peptide 
VTGRFAGHPAAQ exerted the lowest antioxidant activ-
ity. His-containing peptide activity may be attributed to a 
hydrogen-donating ability, peroxyl radical trapping and/
or the metal ion-chelating ability of the imidazole group. 
It may be speculated that the His residue in the peptide 
shows no reactivity against oxidation without the C-ter-
minal segment. For example, the deletion of His residue 
located at the C-terminal in the amino acid sequence 
from synthetic analogs of peptides isolated from soybean 
protein decreased their antioxidant activity (Chen et al. 
1996).
Substances with ACE inhibitory potency are mainly zinc 
chelators (or either a thiol, phosphate, carboxylate oxy-
gen), hydrogen-bond and carboxyl-terminal group donors. 
Therefore, the amino acid sequence strongly affects the 
Table 2  Synthetic peptide data Sequence MS analysis RP-HPLC analysis
m/z m/z calculated Retention time (min) Purity (%)
YINQMPQKSREA 1,464.7343 1,464.7269 [M+H]+ 13.948 96.0
732.8655 732.8674 [M+2H]2+
488.9141 488.9142 [M+3H]3+
VTGRFAGHPAAQ 1,211.6318 1,211.6285 [M+H]+ 12.948 97.0
606.3164 606.3182 [M+2H]2+
404.5485 404.5481 [M+3H]3+
YINQMPQKSRE 1,393.6923 1,393.6898 [M+H]+ 13.243 91.0
697.3487 697.3488 [M + 2H]2+
465.2355 465.2352 [M + 3H]3+
IYEAVNKVSPRAGQF 1,678.8604 1,678.8971 [M+H]+ 19.557 99.0
839.9484 839.9498 [M+2H]2+
560.3026 560.3024 [M+3H]3+
Table 3  Biological activity of synthetic peptides
All data were expressed as mean values (n = 3)
Values sharing the same letter are not significantly different at p < 0.05
Mean values with different letters in the same column are significantly different at p ≤ 0.05
The bolded letters at the peptide sequence represent hydrophobic and positively charged residues
NA no activity
Peptide Enzyme inhibitory activity (IC50) Antioxidant activity
ACE (µg/mL) α-Glucosidase  
(µg/mL)






YINQMPQKSRE 10.1a 1,694.3a 222.8a 2.3c 59.0b 37.0a
YIEAVNKVSPRAGQF 9.4a NA NA 2.2c 61.0b 25.2b
YINQMPQKSREA 12.6b 454.6b 355.8b 1.8b 76.0a 8.5c
VTGRFAGHPAAQ 27.3c 365.4c 1,402.2c 1.5a 58.0b NA
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potential ACE inhibition. According to FitzGerald, Murray 
and Walsh (2004), a glutamic acid residue at the C-terminal 
positions additionally contributes to the ACE inhibitory 
potency of the peptides. This is related to the ability of Glu 
to chelate zinc ions, a component of the active site of the 
angiotensin-converting enzyme. This may explain the high 
activity of peptide YINQMPQKSRE (IC50 = 10.1 µg/mL).
According to reports from other authors, particular pep-
tides with hydrophobic amino acids (aromatic or branched 
side chains) in the sequence take part in the inhibition of 
ACE (Kumar et al. 2010). Moreover, as the activity of 
ACE is to cleave the C-terminal dipeptide of oligopeptide 
substrates, the inhibitory potential of peptides is strongly 
influenced by their C-terminal tripeptide sequences (Ni 
et al. 2012). The most potent ACE inhibitors contain 
hydrophobic amino acid residues at their three C-terminal 
positions (Rohrbach et al. 1981). In our study, peptide 
IYEAVNKVSPRAGQF contained two valine residues in 
the sequence and phenylalanine residues at the C-terminal 
tripeptide sequence, and all the isolated peptides contained 
one proline in their sequence.
Food components with α-glucosidase and DPP-IV inhib-
itory activities may represent nutraceutical effect on diabe-
tes. Alkaline protease hydrolysates from sardine muscle 
(IC50 = 48.7 mg/mL), chicken essence (IC50 = 471.4 mg/
mL) or yogurt (IC50 = 519.8 mg/mL) showed potent 
α-glucosidase inhibitory activity (Matsui et al. 1996). 
Recently, Yu et al. (2012) described eight novel antidiabetic 
peptides from ovalbumin, amongst them the most potent 
peptide KLPGF had α-glucosidase inhibitory activity of 
IC50 = 59.5 µmol/L. Our results indicate that egg yolk 
proteins also may be a worthwhile source of peptides with 
α-glucosidase and DPP-IV inhibitory activity.
To date, no clear dependencies have been found 
between the structure and activity of peptides with poten-
tial α-glucosidase and DPP-IV inhibitory activities due to 
the limited knowledge of the chemical structures of those 
peptides.
Conclusion
The purification and characterization of egg yolk protein 
by-product, from the ethanol extraction of phospholip-
ids (YP) derived peptides, by precipitation, ion-exchange, 
RP-HPLC and MALDI-ToF mass spectrometry has lead 
to the detection of peptide sequences: YINQMPQKSRE, 
YIEAVNKVSPRAGQF, YINQMPQKSREA and VTGRF-
AGHPAAQ. To validate the biological activity of the YP-
derived peptides, they were chemically synthesized. In the 
course of our studies on antioxidant, ACE inhibitory and 
antidiabetic activities (with α-glucosidase and DPP-4 inhib-
itory activity), we have successfully revealed that peptide 
YIEAVNKVSPRAGQF showed mild inhibitory activity 
against ACE (IC50 = 9.4 µg/mL). Peptide YINQMPQKSRE 
showed the strongest antioxidant and DPP-IV inhibitory 
activities The DPPH free radical scavenging, iron chelating 
and DPP-IV inhibitory activity reached: 2.3 µM Troloxeq/mg 
and 37.4 µg Fe2+/mg and IC50 = 222.8 µg/mL, respectively. 
Peptide VTGRFAGHPAAQ showed significant antidia-
betic activity against α-glucosidase (IC50 = 365.4 µg/mL). 
The current study suggests that peptides from YP have the 
potential as suitable candidates for further investigations 
as natural and multifunctional substances to control diet-
related diseases.
Acknowledgments Project “Innovative technologies in the produc-
tion of biopreparations based on new genera- tion eggs,” Innovative 
Economy Operational Programme Priority 1.3.1, thematic area “Bio”, 
co-financed by the European Union through the European Regional 
Development Fund within the Innovative Economy Operational 
Programme, 2007–2013. Project supported by Wroclaw Centre of 
Biotechnology, programme The Leading National Research Centre 
(KNOW) for years 2014–2018.
Conflict of interest This work is free from any conflict of interest.
Open Access This article is distributed under the terms of the Crea-
tive Commons Attribution License which permits any use, distribu-
tion, and reproduction in any medium, provided the original author(s) 
and the source are credited.
References
Benzie IFF, Strain JJ (1996) The ferric reducing ability of plasma 
(FRAP) as a measure of “Antioxidant Power”: the FRAP assay. 
Anal Biochem 293:70–76
Cai H, Harrison DG (2000) Endothelial dysfunction in cardiovascular 
diseases: the role of oxidant stress. Circ Res 87:840–844
Chen HM, Muramoto K, Yamauchi F, Nokihara K (1996) Antioxidant 
activity of designer peptides based on the antioxidative peptide 
isolated from digestion of a soybean protein. J Aric Food Chem 
44:2619–2623
Davalõs A, Miguel M, Bartolome B, López-Fandinˇo R (2004) Anti-
oxidant activity of peptides derived from egg white proteins by 
enzymatic hydrolysis. J Food Prot 67:1939–1944
Fujita H, Yokoyama K, Yoshikawa M (2000) Classification and anti-
hypertensive activity of angiotensin I-converting enzyme inhibi-
tory peptides derived from food proteins. J Food Sci 65:564–569
Gładkowski W, Chojnacka A, Wawrzen´czyk C (2011) The enzymatic 
modification of fatty acid profile in egg-yolk phosphatidylcho-
line. In: 9th Euro Fed Lipid Congress: oils, fats and lipids for a 
healthy and sustainable world. Rotterdam, Holand, 18.09–21.09
Hadi AR, Carr CS, Suwaidi JA (2005) Endothelial dysfunction: car-
diovascular risk factors, therapy, and outcome. Vasc Health Risk 
Manag 1(3):183–198
Jiang Y, Noh SK, Koo SI (2001) Egg phosphatidylcholine decreases the 
lymphatic ab- sorption of cholesterol in rats. J Nutri 131:2358–2363
Kumar R, Kumar A, Sharma R, Baruwa A (2010) Pharmacological 
review on natural ACE inhibitors. Der Pharm Lettre 2(2):273–293
Lacroix IME, Li-Chan ECY (2012) Evaluation of the potential of 
dietary proteins as precursors of dipeptidyl peptidase (DPP)-IV 
inhibitors by an in silico approach. J Funct Foods 4(2):403–422
380 A. Zambrowicz et al.
1 3
Lesnierowski G, Cegielska Radziejewska R, Kijowski J (2004) Ther-
mally and chemically modified lysozymeand its bacteriostatic 
activity. World’s Poult Sci J 60:303–309
Li GH, Le GW, Shi YH, Shrestha S (2004) Angiotensin I-converting 
enzyme inhibitory peptides derived from food proteins and their 
physiological and pharmacological effects. Nutri Res 24:469–486
Lowry OH, Rosebrough NJ, Farr AL, Randal RJ (1951) Protein meas-
urement with the Folin phenol reagent. J Biol Chem 193:265–275
Lu J, Sawano Y, Miyakawa T, Xue YL, Cai MY, Egashira Y, Ren DF, 
Tanokura M (2010) One-week antyhipertensive effect of Ile-
Gln-Pro in spontaneously hypertensive rats. J Agric Food Chem 
59:559–563
Matsui T, Yoshimoto C, Osajima K, Oki T, Osjima Y (1996) In vitro 
survey of alpha- glucosidase inhibitory food components. Biosci 
Biotech Biochem 60(12):2019–2022
Miguel M, Recio I, Gomez-Ruiz JA, Ramos M, Lopez-Fandino R 
(2004) Angiotensin I-converting enzyme inhibitory activity of 
peptides derived from egg white proteins by enzymatic hydroly-
sis. J Food Prot 67:1914–1920
Mine Y, Kovaks-Nolan J (2006) New insights in biologically active 
proteins and peptides derived from hen egg. World Poult Sci J 
62(1):87–95
Ni H, Li L, Liu G, Hu SQ (2012) Inhibition mechanism and model of 
fan angiotensin I-converting enzyme (ACE)-inhibitory hexapep-
tide from yeast (Saccharomyces cerevisiae). PLoS One 7:e37077
Ondetti MA, Cushman DWV (1999) Design of angiotensin convert-
ing enzyme inhibitors. Nature Med 5(10):1110–1112
Park PJ, Jung WK, Nam KS, Shahidi F, Kim SK (2001) Purifica-
tion and characterization of antioxidative peptides from protein 
hydrolysate of lectin-free egg yolk. JAOCS 78(6):651–656
Rao S, Sun J, Liu Y, Zeng H, Su Y, Yang Y (2012) ACE-inhibitory 
peptides and antioxidant peptides derived from in vitro diges-
tion hydrolysate of hen egg white lysozyme. Food Chem 
135:1245–1252
Rohrbach MS, Williams EB, Rolstad RA (1981) Purification and sub-
strate specificity of bovine angiotensin-converting enzyme. J Biol 
Chem 256:225–230
Sakanaka S, Tachibana Y (2006) Active oxygen scavenging activity of 
egg-yolk protein hydrolysates and their effects on lipid oxidation 
in beef and tuna homogenates. Food Chem 95:243–249
Sharma S, Singh R, Rana S (2011) Bioactive peptides: a review. Int J 
Bioautomation 15(4):223–250
Siepka E, Bobak Ł, Trziszka T (2010) Frakcjonowanie z˙ółtka w celu 
pozyskiwania preparatów wzbogaconych w substancje biologic-
znie aktywne. ZTNJ 6(73):158–167 (in polish)
Silvestre MPC (1996) Review of methods for the analysis of protein 
hydrolysates. Food Chem 60:263–271
Ting BPCP, Mine Y, Juneja LR, Okubo T, Gauthier FP, Pouliot Y 
(2011) Comparative composition and antioxidant activity of pep-
tide fractions obtained by ultrafiltration of egg yolk protein enzy-
matic hydrolysates. Membranes 1:149–161
Touyz RM, Tabet F, Schiffrin EL (2003) Redox-dependent signaling 
by angiotensin II and vascular remodeling in hypertension. Clin 
Exp Pharmacol Physiol 30:860–886
Xu X, Katayama S, Mine Y (2007) Antioxidant activity of tryptic 
digests of hen egg yolk phosvitin. J Sci Food Agric 87:260–2604
Yen GC, Chen HY (1995) Antioxidant activity of various tea extracts 
in relation to their antimutagencity. J Agric Food Chem 43:27–32
Yoshii H, Tachi N, Ohba R, Sakamura O, Takeyama H, T Itan (2001) 
Antihypertensive effect of ACE inhibitory oligopeptides from 
chicken egg yolks. Comp Biochem Physiol Toxicol Pharmacol 
128(1):27–33
You SJ, Wu J (2011) Angiotensin-I converting enzyme inhibitory and 
antioxidant activities of egg protein hydrolysates produced with 
gastrointestinal and nongastrointestinal enzymes. J Food Sci 
76(6):801–807
Yu Z, Yin Y, Zhao W, Yu Y, Liu B, Liu J, Chen F (2011) Novel pep-
tides derived from egg white protein inhibiting alpha-glucosidase. 
Food Chem 129(4):1376–1382
Yu Z, Liu B, Zhao W, Yin Y, Liu J, Chen F (2012) Primary and sec-
ondary structure of novel ACE-inhibitory peptides from egg 
white protein. Food Chem 133:315–322
Zambrowicz A, Trziszka T (2010) Aktywnos´ć przeciwutleniaja˛ca 
enzymatycznych hydrolizatów preparatu foswitynowego otrzy-
manego z jaj kurzych. Acta Sci Pol Biotechnol 9(3):27–36 (in 
polish)
Zambrowicz A, Pokora M, Eckert E, Szołtysik M, Da˛browska A, Chr-
zanowska J, Trziszka T (2012) The antioxidant and antimicrobial 
activity of lecithin free egg yolk pro- tein preparation hydro-
lysates obtained with digestive enzymes. Funct Foods Health Dis 
J 2(12):487–500
Zambrowicz A, Pokora M, Eckert E, Szołtysik M, Da˛browska A, Chr-
zanowska J, Trziszka T (2013) Antioxidative peptides derived 
from denaturated egg white protein. Ital J Food Sci 2(25):169–180
